|
WO2020171757A1
|
|
Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
|
|
WO2019245444A1
|
|
Base-modified cytidine nucleotides for leukemia therapy
|
|
JP2020011947A
|
|
Base-modified cytidine nucleotides for leukemia therapy
|
|
US2020399295A1
|
|
Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
|
|
WO2018226150A1
|
|
Pyrazolopyrimidine as malt-1 inhibitors
|
|
WO2018141749A1
|
|
Therapeutic applications of malt1 inhibitors
|
|
WO2018038668A1
|
|
Respiratory syncytial virus inhibitors
|
|
WO2018038667A1
|
|
Respiratory syncytial virus inhibitors
|
|
AU2017227516A1
|
|
Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
|
|
WO2017018924A1
|
|
Respiratory syncytial virus inhibitors
|
|
BR112017018837A2
|
|
nucleotide phosphoramidate formula
|
|
WO2016140615A1
|
|
Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c
|
|
US2017275322A1
|
|
Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
|
|
TW201945378A
|
|
Prodrugs for the treatment of cancer
|
|
KR20170046736A
|
|
Dioxolane analogues of uridine for the treatment of cancer
|
|
TW201815396A
|
|
Hcv polymerase inhibitors
|
|
TW201620923A
|
|
Hcv polymerase inhibitors
|
|
WO2015056213A1
|
|
Hcv polymerase inhibitors
|
|
SE1451080A1
|
|
Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
|
|
CA2921899A1
|
|
Hcv polymerase inhibitors
|
